Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,920 | $0.00 Strike: $117.00 | $0.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · derivative · entry 10 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 Underlying: Bio-Rad A Common Stock · 1,920 shares Expires 2023-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning on September 11, 2014. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,600 | $0.00 Strike: $107.32 | $0.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · derivative · entry 9 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Underlying: Bio-Rad A Common Stock · 2,600 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in five equal annual installments beginning on September 12, 2013. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 1,332 | $215.00 | $286,380.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 8 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,028.3235 Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,600 | $139.56 | $223,296.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 7 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,360.3235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 1,891 | $215.00 | $406,565.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 6 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,760.3235 Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 2,400 | $119.54 | $286,896.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 5 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,651.3235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 1,502 | $215.00 | $322,930.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 4 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,251.3235 Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,920 | $117.00 | $224,640.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,753.3235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 1,978 | $215.00 | $425,270.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,833.3235 Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:13 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 2,600 | $107.32 | $279,032.00 |
DisclosureSEC source: 0001315406-17-000014 · edgar.xml · nonDerivative · entry 1 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,811.3235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 37.1639 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2017. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:44 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
OtherBio-Rad B Common Stock | 20,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-17-000012 · edgar.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,451 F3 · shares: Distribution from DANSA Partners LTD to the reporting person who is a limited partner. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:40 UTC |
SCHWARTZ STEVEN D10% owner
|
OtherBio-Rad B Common Stock | 20,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-17-000010 · edgar.xml · nonDerivative · entry 3 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,892 F2 · shares: Distribution from DANSA Partners LTD to the reporting person who is a limited partner. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:18 UTC |
SCHWARTZ ALICE NDirector · 10% owner
|
OtherBio-Rad B Common Stock | 41,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-17-000008 · edgar.xml · nonDerivative · entry 9 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By DANSA Partners LTD Disclosed balance after: 0 F2 · shares: Distribution of shares by DANSA Partners LTD to its limited partners. The reporting person is a general partner of DANSA Partners LTD. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 20:18 UTC |
Hall ShannonExecutive Vice President
|
SaleBio-Rad A Common Stock | 900 | $222.65 | $200,386.53 |
DisclosureSEC source: 0001652252-17-000035 · edgar.xml · nonDerivative · entry 1 Hall Shannon · CIK 0001621222 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560.1019 F1 · balance_after: Includes 69.9966 shares acquired under the Bio-Rad Laboratories employee stock purchase plan on March 31, 2017. Read SEC document |
| May 26, 2017 Filed May 30, 2017 16:22 UTC |
Hinckley Greg KDirector
|
PurchaseBio-Rad A Common Stock | 500 | $219.58 | $109,792.45 |
DisclosureSEC source: 0001315406-17-000006 · edgar.xml · nonDerivative · entry 1 HINCKLEY GREGORY K · CIK 0001239182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| May 23, 2017 Filed May 25, 2017 17:22 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $75.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000033 · edgar.xml · derivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 37,500 shares Expires 2017-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in five equal annual installments beginning on August 1, 2008. Read SEC document |
| May 23, 2017 Filed May 25, 2017 17:22 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 25,605 | $216.00 | $5,530,680.00 |
DisclosureSEC source: 0001652252-17-000033 · edgar.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,863 Read SEC document |
| May 23, 2017 Filed May 25, 2017 17:22 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 37,500 | $75.00 | $2,812,500.00 |
DisclosureSEC source: 0001652252-17-000033 · edgar.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 16:10 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 2,113 | $220.23 | $465,346.20 |
DisclosureSEC source: 0001315406-17-000004 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,543 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.75, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · derivative · entry 12 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2018-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested in five equal annual installments beginning on June 11, 2009. Read SEC document |
| May 11, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
SaleBio-Rad A Common Stock | 3,500 | $220.17 | $770,590.10 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 8 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,174.1596 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.35 inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $88.00 | $308,000.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 7 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,674.1596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $98.04 | $0.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · derivative · entry 11 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2021-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in five equal annual installments beginning on November 4, 2012. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $84.57 | $0.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · derivative · entry 10 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2020-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in five equal annual installments beginning on September 8, 2011. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $74.27 | $0.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · derivative · entry 9 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2019-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning on June 10, 2010. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 2,563 | $223.00 | $571,549.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 6 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,174.1596 Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $98.04 | $343,140.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 5 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,737.1596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 2,462 | $223.00 | $549,026.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 4 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,237.1596 Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $84.57 | $295,995.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,699.1596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 2,271 | $223.00 | $506,433.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,199.1596 Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $74.27 | $259,945.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 1 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,470.1596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 47.7598 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2017. Read SEC document |
| March 07, 2017 Filed Mar 8, 2017 23:46 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 300 | $196.13 | $58,840.29 |
DisclosureSEC source: 0001652252-17-000008 · edgar.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,760 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $75.32 | $0.00 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · derivative · entry 4 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2017-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning August 1, 2008. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 3,500 | $195.87 | $685,528.20 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · nonDerivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,656 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.11 to $196.40, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $75.32 | $263,620.00 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 998 | $196.16 | $195,771.37 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,656 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.15 to $196.25, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 00:21 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $75.32 | $0.00 |
DisclosureSEC source: 0001652252-17-000004 · edgar.xml · derivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2017-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning on August 1, 2008. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 00:21 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
SaleBio-Rad A Common Stock | 3,500 | $196.34 | $687,188.60 |
DisclosureSEC source: 0001652252-17-000004 · edgar.xml · nonDerivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,922.3998 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.306 to $196.415 inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 00:21 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $75.32 | $263,620.00 |
DisclosureSEC source: 0001652252-17-000004 · edgar.xml · nonDerivative · entry 1 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,422.3998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4.6707 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/31/2016. Read SEC document |
| December 09, 2016 Filed Dec 30, 2016 23:20 UTC |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad B Common Stock | 468 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000044 · edgar.xml · nonDerivative · entry 6 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 439,562 Read SEC document |
| December 09, 2016 Filed Dec 30, 2016 23:18 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 78 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000043 · edgar.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,664 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 09, 2016 Filed Dec 30, 2016 23:18 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 78 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000043 · edgar.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,968 Read SEC document |
| December 09, 2016 Filed Jan 6, 2017 21:35 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 78 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000002 · edgar.xml · nonDerivative · entry 4 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,664 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 09, 2016 Filed Jan 6, 2017 21:35 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 78 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000002 · edgar.xml · nonDerivative · entry 3 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,304 Read SEC document |
| November 09, 2016 Filed Nov 9, 2016 23:00 UTC |
STARK JAMES RVP, Corporate Controller
|
SaleBio-Rad A Common Stock | 1,299 | $171.42 | $222,674.84 |
DisclosureSEC source: 0001652252-16-000144 · edgar.xml · nonDerivative · entry 1 STARK JAMES R · CIK 0001248083 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 23:45 UTC |
Hall ShannonExecutive Vice President
|
SaleBio-Rad A Common Stock | 84 | $165.62 | $13,912.08 |
DisclosureSEC source: 0001652252-16-000142 · edgar.xml · nonDerivative · entry 2 Hall Shannon · CIK 0001621222 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390.1053 F3 · shares: Sold by the Issuer on behalf of the Reporting Person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 19:28 UTC |
STARK JAMES RVP, Corporate Controller
|
SaleBio-Rad A Common Stock | 76 | $165.62 | $12,587.12 |
DisclosureSEC source: 0001652252-16-000138 · edgar.xml · nonDerivative · entry 2 STARK JAMES R · CIK 0001248083 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299 F2 · shares: Sold by the issuer on behalf of the reporting person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 18:56 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 91 | $165.62 | $15,071.42 |
DisclosureSEC source: 0001652252-16-000134 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,654 F2 · shares: Sold by the issuer on behalf of the reporting person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 18:42 UTC |
HERTIA JOHNExecutive Vice President
|
SaleBio-Rad A Common Stock | 227 | $165.62 | $37,595.74 |
DisclosureSEC source: 0001652252-16-000130 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,630 F2 · shares: Sold by the issuer on behalf of the reporting person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 18:27 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 88 | $165.62 | $14,574.56 |
DisclosureSEC source: 0001652252-16-000126 · edgar.xml · nonDerivative · entry 2 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,060 F2 · shares: Sold by the issuer on behalf of the reporting person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.